EICHORCondition: Chronic Graft-versus-host-disease · Sponsor: Incyte Corporation
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Medical University of Graz | Graz, Austria | — |
| Medizinische Universitaet Innsbruck - Universitaetsklinik Fuer Innere Medizin Iii | Innsbruck, Austria | — |
| Krankenhaus Der Elisabethinen Linz Gmbh | Linz, Austria | — |
| Medizinische Universitat Wien, Universitatsklinik Fur Innere Medizin I | Vienna, Austria | — |
| St. Anna Childrens Hospital | Vienna, Austria | — |
| Az Sint-Jan Brugge Av | Bruges, Belgium | — |
| Chu Ucl Namur Site Godinne | Godinne-mont, Belgium | — |
| Universitair Ziekenhuis Leuven | Leuven, Belgium | — |
| Chu Liege -Centre Hospitalier Universitaire Sart Tilman | Liège, Belgium | — |
| Algemeen Ziekenhuis Delta | Roeselare, Belgium | — |
| Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc | Woluwe-Saint-Lambert, Belgium | — |
| Fakultni Nemocnice Hradec Kralove | Hradec Králové, Czechia | — |
+ 118 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06821542